AVP-786 matching placebo, AVP-786 clinical trials

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type

This study is testing a new medicine, AVP-786, for people with Alzheimer's disease who experience agitation. It aims to see if the medicine can help reduce agitation and if it's safe to use. Half the participants will get the new medicine and half will get a dummy pill.